Table 4.

Antimicrobial Susceptibilities of E. Anophelis Isolates Determined by the Broth Microdilution Method

Antimicrobial Agents	Breakpoint (μg/mL)		MIC (μg/mL)			Susceptibility (%)
	Susceptible	Resistant	Range	50%	90%	Susceptible	Intermediate	Resistant
Piperacillin	≤16	≥128	16–128	32	64	17.9	74.4	7.7
Piperacillin-TZB	≤16	≥128	4–64	16	32	71.8	28.2	0
Ceftazidime	≤8	≥32	128 to >256	>256	>256	0	0	100
Ceftazidime-CLA	≤8	≥32	32 to >256	>256	>256	0	0	100
Ceftazidime-AVI	≤8	≥16	64 to >256	>256	>256	0	0	100
Cefepime	≤8	≥32	32 to >256	>256	>256	0	0	100
Cefepime-CLA	≤8	≥32	32 to >256	256	>256	0	0	100
Aztreonam	≤8	≥32	>256	>256	>256	0	0	100
Aztreonam-AVI	≤8	≥16	>256	>256	>256	0	0	100
Imipenem	≤4	≥16	16 to >256	64	128	0	0	100
Meropenem	≤4	≥16	16 to >256	64	256	0	0	100
Levofloxacin	≤2	≥8	0.5–32	8	16	38.5	2.6	60.0
Ciprofloxacin	≤1	≥4	0.5 to >256	64	256	30.8	2.6	66.6
Minocycline	≤4	≥16	0.25–1	0.5	1	100	0	0
Tigecycline	≤2	≥8	2–8	4	4	10.3	82.1	7.6
Fosfomycin	≤32	>32	>256	>256	>256	0	0	100
Colistin	≤2	>2	>256	>256	>256	0	0	100
Vancomycin	≤2	≥16	8–32	16	32	0	20.5	79.5
Rifampicin	≤1	≥4	1–32	2	16	20.5	33.3	46.2

Abbreviations: MIC, minimum inhibitory concentration; TZB, tazobactam at a fixed concentration of 4 μg/mL; AVI, avibactam at a fixed concentration of 4 μg/mL; CLA, clavulanic acid at a fixed concentration of 2 μg/mL.